Cibus マネジメント

マネジメント基準チェック /24

Cibusの CEO はRory Riggsで、 Jan2001年に任命され、の在任期間は 23.83年です。の年間総報酬は$ 292.31Kで、 100%給与と0%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の13.12%を直接所有しており、その価値は$ 15.40M 。経営陣と取締役会の平均在任期間はそれぞれ5.1年と1.4年です。

主要情報

Rory Riggs

最高経営責任者

US$292.3k

報酬総額

CEO給与比率	100.0%
CEO在任期間	23.8yrs
CEOの所有権	13.1%
経営陣の平均在職期間	5.1yrs
取締役会の平均在任期間	1.4yrs

経営陣の近況

Recent updates

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Oct 07

Calyxt exploring strategic alternatives

Sep 22

Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Apr 01

Calyxt Needs To Secure More Commercial Partners As Cash Dwindles

Sep 16

CEO報酬分析

Cibus の収益と比較して、Rory Riggs の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$445m
Jun 30 2024	n/a	n/a	-US$292m
Mar 31 2024	n/a	n/a	-US$286m
Dec 31 2023	US$292k	US$292k	-US$268m

報酬と市場: Roryの総報酬 ($USD 292.31K ) は、 US市場 ($USD 652.28K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Roryの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

Rory Riggs (71 yo)

23.8yrs

在職期間

US$292,314

報酬

Mr. Rory Balfour Riggs, MBA, serves as Chief Executive Officer of Cibus, Ltd. since October 2021. He is Co-Founder at Cibus, Inc. and is its Chief Executive Officer and Chairman since June 1, 2023.Mr. Rig...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Rory Riggs	Co-Founder	23.8yrs	US$292.31k	13.12% $ 15.4m
Peter Beetham	Co-Founder	1.4yrs	US$292.31k	0.29% $ 336.3k
Greg Gocal	Co-Founder	8.8yrs	US$266.01k	0.24% $ 279.4k
Jason Stokes	Chief Legal Officer	less than a year	データなし	データなし
Rosa Kim	Senior Vice President of Legal	no data	データなし	データなし
James Radtke	Senior Vice President of Product Development	no data	データなし	データなし
Tony Moran	Senior Vice President of International Development	no data	データなし	データなし
Norm Sissons	Senior Vice President of Seed & Traits	no data	データなし	データなし
Noel Sauer	Senior Vice President of Research	no data	データなし	データなし
Sean O'Connor	Senior VP and President & CEO of Nucelis	no data	データなし	データなし

5.1yrs

平均在職期間

61yo

平均年齢

経験豊富な経営陣: CBUSの経営陣は経験豊富で経験豊富です（平均在職期間は5.1年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Rory Riggs	Co-Founder	1.4yrs	US$292.31k	13.12% $ 15.4m
Peter Beetham	Co-Founder	1.4yrs	US$292.31k	0.29% $ 336.3k
Gerhard Prante	Independent Vice Chairman	1.4yrs	データなし	0.27% $ 318.5k
Mark Finn	Lead Independent Director	1.4yrs	データなし	0.25% $ 289.4k
Keith Walker	Independent Director	1.4yrs	データなし	0.32% $ 373.5k
Joseph Ecker	Member of Scientific Advisory Board	no data	データなし	データなし
Jean-Pierre Lehmann	Independent Director	1.4yrs	データなし	6.65% $ 7.8m
Jan Leach	Member of Scientific Advisory Board	no data	データなし	データなし
Stephen Howell	Member of Scientific Advisory Board	no data	データなし	データなし
Richard Meagher	Member of Scientific Advisory Board	no data	データなし	データなし

1.4yrs

平均在職期間

78yo

平均年齢

経験豊富なボード: CBUSの取締役会は経験豊富ではない ( 1.4年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Cibus マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Cibus, Inc. Announces CFO Changes, Effective September 30, 2024

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc., Annual General Meeting, May 30, 2024

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Cibus, Inc. Appoints Jim Collins to Board of Directors

Recent updates

Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola

Consensus revenue estimates increase by 71%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2024

Cibus, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

New major risk - Share price stability

Cibus, Inc. has completed a Follow-on Equity Offering in the amount of $12 million.

Cibus, Inc. Announces CFO Changes, Effective September 30, 2024

Consensus EPS estimates fall by 12%

Price target decreased by 10% to US$19.75

New major risk - Financial position

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Cibus, Inc. Expands Its Intellectual Property Coverage for Plant Gene Editing and Traits

New minor risk - Share price stability

Cibus’ White Mold (Sclerotinia) Resistance Trait Program Confirms Important Milestone for Next Generation Gene Edits in Canola

Full year 2023 earnings released: US$25.95 loss per share (vs US$18.36 loss in FY 2022)

Consensus revenue estimates increase by 18%

Cibus, Inc. Appoints Jason Stokes as Chief Legal Officer, General Counsel and Corporate Secretary

Cibus, Inc. to Report Q1, 2024 Results on May 09, 2024

Cibus, Inc., Annual General Meeting, May 30, 2024

Consensus EPS estimates upgraded to US$3.03 loss, revenue downgraded

Consensus EPS estimates fall by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales

Cibus: Expanding Opportunities And Growing Accessible Market

Cibus, Inc. Announces Successfully Regenerated Plants from Single Cells in Wheat

Cibus, Inc. has filed a Follow-on Equity Offering in the amount of $80 million.

Co-Founder recently bought US$5.5m worth of stock

Cibus, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 15%, EPS downgraded

Price target decreased by 13% to US$22.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cibus, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cibus, Inc. Announces Resignation of Jim Collins as Member of Board of Directors and Member of Nominating and Corporate Governance Committee

Is Cibus, Inc. (NASDAQ:CBUS) Trading At A 44% Discount?

Cibus, Inc. Appoints Jim Collins to Board of Directors

Does Cibus (NASDAQ:CBUS) Have A Healthy Balance Sheet?

Consensus revenue estimates fall by 60%

Second quarter 2023 earnings released: US$3.05 loss per share (vs US$2.66 loss in 2Q 2022)

Cibus, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Price target decreased by 50% to US$18.00

Consensus revenue estimates increase by 46%

New major risk - Shareholder dilution

First quarter 2023 earnings released: US$1.09 loss per share (vs US$1.34 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Cibus Global, Ltd. entered into a definitive merger agreement to acquire Calyxt, Inc. (NasdaqCM:CLXT) from Cellectis S.A. (ENXTPA:ALCLS) and others in a reverse merger transaction.

Calyxt, Inc. Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil

Calyxt Gets 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

High number of new directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.20 loss in 3Q 2021)

Calyxt, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Calyxt, Inc Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants

Calyxt signs agreement with Evologic to scale production of plant-based ingredients

Calyxt exploring strategic alternatives

Consensus forecasts updated

Forecast to breakeven in 2024

Second quarter 2022 earnings released: US$0.053 loss per share (vs US$0.13 loss in 2Q 2021)

Price target increased to US$6.83

Calyxt, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Calyxt Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$4.99

High number of new directors

Calyxt, Inc. Announces Directorate Appointments

Calyxt, Inc. to Report Q1, 2022 Results on May 05, 2022

マネジメント基準チェック /24